Creative Planning
LUCD icon

Creative Planning’s Lucid Diagnostics LUCD Stock Holding History

Creative Planning’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.5K Buy
21,068
+6,648
+46% +$7.17K ﹤0.01% 4185
2026
Q1 		$16.6K Buy
14,420
+2,553
+22% +$3.25K ﹤0.01% 4053
2025
Q4 		$12.9K Sell
11,867
-4
-0% -$4 ﹤0.01% 3864
2025
Q3 		$12K Buy
11,871
+18
+0.2% +$20 ﹤0.01% 3835
2025
Q2 		$13.6K Hold
11,853
– – ﹤0.01% 3608
2025
Q1 		$17.7K Hold
11,853
– – ﹤0.01% 3410
2024
Q4 		$9.7K Buy
+11,853
New +$10.5K ﹤0.01% 3384

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Creative Planning's LUCD Position: Q2 2026 in Review

Creative Planning increased its Lucid Diagnostics (LUCD) stake by 46% in Q2 2026, buying an estimated $7.17K and bringing the position to 21,068 shares worth $22.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4185.

Creative Planning first reported a position in LUCD in Q4 2024 and has held it in 7 quarters since. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • Creative Planning held 21,068 shares of Lucid Diagnostics worth $22.5K as of Q2 2026.
  • Creative Planning bought 6,648 Lucid Diagnostics shares in Q2 2026, an estimated $7.17K.
  • Lucid Diagnostics made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #4185 holding.
  • Creative Planning first reported a position in Lucid Diagnostics in Q4 2024 and has held it in 7 quarters since.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.